[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 20, 2011 NF ENERGY SAVING CORPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Room 3105, Block C, 390 Qingnian Avenue Heping District Shenyang, P.R. China 11000221 (Zip Code) (8624) 2560-9750 (Former Name or Former Address, if Changed Since Last Report) see]
[Jiayuan Announces Share Repurchase Program BEIJING, December22, 2011--- Jiayuan.com International (Jiayuan or thempany) (NASDAQ:TE), operator of the largest onlineting platform in China, today announced that its board of directors has approved a US$10 million share repurchase program. We arenfident in the future of Jiayuans business wentinue to benefit from our clear leadership in Chinas onlineting]
[Jiayuan Announces Share Repurchase Program BEIJING, December22, 2011--- Jiayuan.com International (Jiayuan or thempany) (NASDAQ:TE), operator of the largest onlineting platform in China, today announced that its board of directors has approved a US$10 million share repurchase program. We arenfident in the future of Jiayuans business wentinue to benefit from our clear leadership in Chinas onlineting]
[____________________________________________ SCHEDULE 13D/A (Amendment No. 6) Global Sources Ltd. (Name of Issuer) Common Shares, Par Value $0.01 per share (Title of Class of Securities) G 39300 101 (CUSIP Number) Merle A. Hinrichs c/o Global Sources Ltd. Canon’s Court 22 Victoria Street Hamilton, HM 12 Bermuda with a copy to James J. Clark, Esq. Cahill Gordon & Reindel LLP 80 Pine]
[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals,] [Shaanxi Weinan Aoxing Pharmaceuticals, (formerly Shaanxi Weinan Huaren Pharmaceuticals,) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders Equity F-4 Statement ofsh Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors] [UNAUDITED PRO FORMANDENSEDMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, (NASDAQ GM: BSPM) (Biostar or thempany), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical acquired 100% equity interest (the Acquisition) of Shaanxi Weinan Aoxing Pharmaceutical, (formerly Shaanxi Weinan Huaren Pharmaceutical,) (Shaanxi Weinan) at ash purchasensideration of RMB61 million (approximately $9.5 million).]
[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals,] [Shaanxi Weinan Aoxing Pharmaceuticals, (formerly Shaanxi Weinan Huaren Pharmaceuticals,) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders Equity F-4 Statement ofsh Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors] [UNAUDITED PRO FORMANDENSEDMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, (NASDAQ GM: BSPM) (Biostar or thempany), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical acquired 100% equity interest (the Acquisition) of Shaanxi Weinan Aoxing Pharmaceutical, (formerly Shaanxi Weinan Huaren Pharmaceutical,) (Shaanxi Weinan) at ash purchasensideration of RMB61 million (approximately $9.5 million).]
